Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals develops biotechnology medicines for serious diseases and conditions, with commercial franchises in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. Company news commonly covers CFTR modulators including ALYFTREK and TRIKAFTA, the CRISPR/Cas9 gene-edited therapy CASGEVY, and JOURNAVX, an oral non-opioid pain signal inhibitor.
Updates also track financial results, regulatory approvals and label expansions, reimbursement and patient-access agreements, clinical data presentations, and pipeline programs in kidney disease, neuropathic pain, type 1 diabetes, generalized myasthenia gravis and myotonic dystrophy type 1. Vertex disclosures frequently connect revenue trends with progress across approved products and investigational programs such as povetacicept for IgA nephropathy.
Vertex Pharmaceuticals (Nasdaq: VRTX) announced the publication of Phase 2 study results in the New England Journal of Medicine, evaluating inaxaplin (VX-147) for APOL1-mediated kidney disease (AMKD). The study demonstrated a statistically significant 47.6% mean reduction in proteinuria at 13 weeks compared to baseline, the primary endpoint. Inaxaplin was well tolerated, with common adverse events including headache and back pain. The FDA granted Breakthrough Therapy Designation for inaxaplin, and the ongoing Phase 2/3 trial aims to assess kidney function over two years, with over 100 global sites open for enrollment.
Vertex Pharmaceuticals has received FDA clearance for its Investigational New Drug Application (IND) for VX-264, a new stem cell-derived pancreatic islet cell therapy aimed at treating type 1 diabetes (T1D). This investigational therapy eliminates the need for immunosuppression, potentially expanding its patient base. Vertex plans to initiate a Phase 1/2 clinical trial in mid-2023 to evaluate VX-264's safety and efficacy, following ongoing trials for a similar therapy, VX-880, in Canada and the U.S.
The trial will enroll approximately 17 patients and seeks to understand the therapy's impact on T1D, a condition characterized by the loss of insulin production.
ImmunoGen, Inc. (Nasdaq: IMGN) announced a comprehensive licensing agreement with Vertex Pharmaceuticals (NYSE: VRTX), allowing Vertex to research ImmunoGen's antibody-drug conjugate technology for gene editing applications. Vertex will pay an upfront fee of $15 million and may contribute up to $337 million in option and milestone payments. ImmunoGen retains rights to their technology for other targets. This collaboration aims to enhance the development of gentler conditioning regimens for treating sickle cell disease and beta thalassemia, showcasing ImmunoGen’s innovative potential in the ADC sector.
Vertex Pharmaceuticals (NASDAQ: VRTX) will present at Cowen's 43rd Annual Health Care Conference on March 7, 2023, at 2:50 p.m. ET. The event will feature a live webcast accessible via the Vertex website in the "Investors" section. Vertex is a leading biotechnology company known for developing transformative medicines for serious diseases, particularly cystic fibrosis. The company, founded in 1989 and headquartered in Boston, has a broad pipeline, including therapies for sickle cell disease and type 1 diabetes. Vertex has received recognition for being a top employer in the biotechnology sector.
Vertex Pharmaceuticals announced its 2022 financial results, reporting a 18% increase in product revenue to $8.93 billion, driven by strong uptake of TRIKAFTA/KAFTRIO. GAAP net income rose 42% to $3.32 billion. For 2023, they forecast product revenue between $9.55 billion and $9.7 billion. Notably, Vertex is advancing regulatory submissions for its gene therapy exa-cel in Europe and the U.K., while a rolling BLA submission is ongoing in the U.S. The company anticipates multiple clinical milestones in 2023, emphasizing its commitment to expanding treatments for cystic fibrosis and other serious diseases.
Vertex Pharmaceuticals (NASDAQ: VRTX) will announce its fourth quarter and full year 2022 financial results on February 7, 2023, after market close. A conference call will follow at 4:30 p.m. ET, accessible by phone or via a live webcast on the company's website. Vertex is a leading biotechnology firm focused on innovative therapies for serious diseases, particularly cystic fibrosis. With multiple approved drugs and an extensive pipeline targeting various genetic and severe conditions, Vertex is positioned as a significant player in the biotech sector. The company is also recognized as a top employer within the industry.
Vertex Pharmaceuticals (NASDAQ: VRTX) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 11:15 a.m. ET. The event will include a live webcast accessible through the Vertex website in the 'Investors' section. Vertex is a biotechnology firm focused on developing transformative medicines, particularly for cystic fibrosis. The company has multiple approved therapies and a robust pipeline targeting other serious diseases, including sickle cell disease and type 1 diabetes. Founded in 1989, Vertex is headquartered in Boston.
Vertex Pharmaceuticals has received FDA clearance for its Investigational New Drug (IND) application for VX-522, a novel inhaled mRNA therapy for cystic fibrosis, targeting approximately 5,000 patients who cannot benefit from existing CFTR modulators. A clinical trial evaluating the safety of VX-522 is set to begin in the coming weeks. This breakthrough follows a collaboration with Moderna established in 2016, combining Vertex's expertise in cystic fibrosis and Moderna's mRNA technology to target the underlying cause of the disease.
Vertex Pharmaceuticals and CRISPR Therapeutics announced upcoming oral presentations of clinical data for exagamglogene autotemcel (exa-cel) at the 2022 ASH Annual Meeting. This investigational therapy targets sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Key presentations include efficacy and safety data from Phase 3 trials, with plans for regulatory submissions in the U.S., U.K., and EU by early 2023. The studies highlight the quality of life impacts for patients undergoing treatment.
Vertex Pharmaceuticals (VRTX) and Entrada Therapeutics (TRDA) have announced a global collaboration to develop intracellular EEV therapeutics for myotonic dystrophy type 1 (DM1). Entrada will receive an upfront payment of $224 million along with $26 million in equity and is eligible for future milestone payments totaling up to $485 million. The collaboration focuses on Entrada’s late-stage preclinical candidate, ENTR-701, which aims to address underlying causes of DM1. Vertex will lead further development, manufacturing, and commercialization efforts.